[Peptide vaccine therapy with TLR-9 agonist for patients with esophageal squamous cell carcinoma].
Patients with advanced carcinoma are thought to have an impaired immune surveillance system. Therefore, the potent helper action is required for the induction of an antitumor immune response in such patients. We evaluated the efficacy of CpG-ODN, which is TLR-9 agonist, as cancer vaccine adjuvant through in vitro experiments. We also conducted a phase I clinical trial for patients with advanced esophageal squamous cell carcinoma (ESCC) using peptide vaccine in combination with CpG-B. In vitro experiments showed that CpG-ODN caused various immune-modifications, suggesting an efficacy of CpG-ODN as peptide vaccine adjuvant. Moreover, the immune monitoring data in phase I clinical trial suggested that CpG-B augmented the generation of antigen-specific T cell responses and innate immunity. These data indicated that the vaccination with cancer-testis antigen derived peptide in combination with CpG-B may be useful as a new immunotherapy for patients with advanced ESCC.
Second Dept. of Surgery, School of Medicine, Wakayama Medical University.
Masahiro
M
Katsuda
Makoto
M
Iwahashi
Kenji
K
Matsuda
Motoki
M
Miyazawa
Mikihito
M
Nakamori
Masaki
M
Nakamura
Teiji
T
Naka
Toshiyasu
T
Ojima
Takeshi
T
Iida
Hiroki
H
Yamaue
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000628:therapy*; D004938:Esophageal Neoplasms / Q000276:immunology / Q000628:therapy*; D006801:Humans; D016233:Immunotherapy, Active; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage / Q000627:therapeutic use*; D051217:Toll-Like Receptor 9 / Q000819:agonists*; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D019496:Cancer Vaccines; D009838:Oligodeoxyribonucleotides; C495371:TLR9 protein, human; D051217:Toll-Like Receptor 9; D022223:Vaccines, Subunit